HEM Pharma Prepares for KOSDAQ Listing Following Successful Technical Evaluation
Microbiome healthcare expert HEM Pharma, led by CEO Joseph Joseph, is gearing up for its listing on the KOSDAQ after passing the rigorous technical evaluation process.
On the 1st of February, HEM Pharma announced that it had fulfilled the requirements for standard listing, thereby gaining recognition for its technologically advanced and competitive nature. This recognition came from professional evaluation agencies Nice D&B and Korea Technology Credit Rating, both of which are designated by the Korea Exchange. The comprehensive evaluation of technology and business feasibility is a crucial step in determining the ranking of KOSDAQ technology growth companies and selecting promising technology companies.
Having successfully completed the technical evaluation, HEM Pharma plans to consult with Shinhan Investment & Securities, the listing manager, to determine the timing for the preliminary examination. Together with thorough preparations for the listing, the company will submit an application for a preliminary listing examination to the Korea Exchange.
HEM Pharma CEO Joseph Joseph: Technological Excellence Recognized
CEO Joseph Joseph expressed his satisfaction with the outcome of the evaluation, particularly praising the launch and technology of ‘my LAB by Nutrilite’. Developed by HEM Pharma, this is Korea’s only dual analysis intestinal health solution customized probiotics, which utilize the patented technology ‘PMAS (Personalized Pharmaceutical Meta-Analytical Screening)’ developed by the company. The technological completeness of this product played a significant role in the evaluation, highlighting its business and growth potential.
Furthermore, CEO Joseph emphasized HEM Pharma’s commitment to research and development, specifically mentioning two promising new drugs under development. HEMP-001, a drug for the treatment of depression that has completed global phase 2 clinical trial design (IND) approval, and HEMP-002, a drug for Lower Anterior Resection Syndrome (LARS) treatment. These drugs, along with their innovative living biotherapeutic product (LBP) new drug pipeline, demonstrate HEM Pharma’s dedication to sustainable growth and open innovation in the field.
HEM Pharma, founded in 2017, is primarily led by Chief Technology Officer (CTO) Wilhelm Holzapfel, a renowned microbiome scholar, in addition to CEO Joseph Joseph, who holds a Ph.D. The company’s strong leadership and focus on cutting-edge technology have positioned it as a key player in microbiome healthcare and drug development.
Expert on microbiome healthcare and on the new drug development platform HEM Pharma(HEM Pharma, CEO Joseph Joseph) is preparing for listing on the KOSDAQ by passing the technical evaluation.
According to HEM Pharma on the 1st, the company met the requirements for standard listing by being recognized for its technological completeness and competitiveness by Nice D&B and Korea Technology Credit Rating, two professional evaluation agencies designated by the Korea Exchange . Technological evaluation is an important portal for ranking KOSDAQ technology growth companies in particular, and is a system to select promising technology companies by evaluating technology and business feasibility.
Based on the results of the technical evaluation, HEM Pharma plans to decide on the timing of the preliminary examination with Shinhan Investment & Securities, the listing manager, and submit an application for a preliminary listing examination to the Korea Exchange along with preparations for serious listing.
Photo = HEM Pharma
Josephpicture> The CEO said, “Launch and technology of ‘my LAB by Nutrilite’, Korea’s only dual analysis intestinal health solution customized probiotics using ‘PMAS (Personalized Pharmaceutical Meta-Analytical Screening)’, a patented technology built by the company .Through the completeness of ‘, the business and growth potential was recognized in this technology evaluation.”
CEO Ji continued, “HEMP-001 (development code name), a new drug for the treatment of depression that has completed global phase 2 clinical trial design (IND) approval, and ‘HEMP-002’, a new drug for Lower Anterior Resection Syndrome (. LARS) treatment. Based on our independent LBP (Living Biotherapeutic Product) new drug pipeline through various candidates such as ‘, we will continue to strive to ensure sustainable growth, such as open innovation and technology transfer, through research investment and develop and expand pipelines, and jointly strengthen a research network.”
Meanwhile, HEM Pharma, founded in 2017, is primarily operated by Chief Technology Officer (CTO) Wilhelm Holzapfel, a world-renowned microbiome scholar, and CEO Joseph Joseph, who has a Ph. D.
#HEM #Pharma #passed #technical #evaluation #Full #KOSDAQ #technology #special #list
